Transplant Care

Graftix Division Introduction

Immunosuppressant (IS) Introduction:

Viatris Transplant Care business redefines the healthcare landscape by planting hope and life in millions of patients

Graft rejection is the major barrier to successful transplantation1. Viatris in collaboration with strategic partners and sales and marketing efforts helps patients to access quality medicines on time and at an affordable rate.2

The Viatris India transplant care division strives to empower individuals to live life minus the fear of graft failure by optimizing immunosuppressant balance. Our dedicated patient support program adds an edge to the care that we extend.

Our immunosuppressant range of products:

  • Mylimus® (Tacrolimus)
  • Lanolimus® (Everolimus)
  • Graftide M® (Mycophenolate mofetil)
  • Graftide S® (Mycophenolate sodium)

Graftix logo

References:

  1. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation. 2012 Jan 15;93(1):1-10.
  2. Viatris: Global Healthcare Company. Available at: https://www.viatris.com/en. Accessed on: 22 February 2022.